AXL and breast carcinoma: AXL’s involvement in the EMT process is not limited to its function as a downstream effector, i.e., an effector activated only when the transition to a mesenchymal phenotype has to be promoted; in breast cancer stem cells (BCSCs), indeed, it also exerts a direct influence in this phenomenon.